First Trust Advisors LP Travere Therapeutics, Inc. Transaction History

First Trust Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $207,728 - $306,975	13,577 New	13,577 $208,000
Q4 2022 Feb 09, 2023	SELL	$18.47 - $26.14 $630,233 - $891,949	-34,122 Reduced 31.93%	72,743 $1.53 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $1.32 Million - $1.65 Million	57,491 Added 116.44%	106,865 $2.63 Million
Q2 2022 Aug 12, 2022	BUY	$20.94 - $30.01 $1.03 Million - $1.48 Million	49,374 New	49,374 $1.2 Million
Q3 2021 Nov 15, 2021	SELL	$12.98 - $25.03 $295,437 - $569,707	-22,761 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $1.27 Million - $2.38 Million	-90,087 Reduced 79.83%	22,761 $332,000
Q1 2021 May 14, 2021	BUY	$23.37 - $31.77 $1.58 Million - $2.14 Million	67,424 Added 148.43%	112,848 $2.82 Million
Q4 2020 Feb 02, 2021	BUY	$19.17 - $27.87 $870,778 - $1.27 Million	45,424 New	45,424 $1.24 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.